Competitive Binding LC-MS for Biologic CQA Variant Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for evaluating critical quality attributes (CQAs) of biologics, such as therapeutic monoclonal antibodies, are inefficient and low-throughput, requiring laborious enrichment and evaluation of product-related impurities, which complicates the characterization of quality control attributes and impacts product purity and stability.
Innovation Solution
A competitive binding-LC-MS method is developed, where a protein of interest is contacted with an insufficient amount of capture molecule, and the flow-through is subjected to separation and quantification using ion exchange chromatography and mass spectrometry, enabling high-throughput identification of product-related variants with impaired binding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If product-related impurities are enriched and evaluated individually using current methods, then measurement precision of CQAs is improved, but productivity is reduced
Solution Approach 1:
The patent combines multiple evaluation functions into a single competitive binding assay. Multiple product-related variants (aggregates, fragments, charge variants, PTMs) are simultaneously assessed in one experiment by comparing their binding behavior to the target, eliminating the need for separate enrichment and evaluation steps for each variant type.
Solution Approach 2:
The competitive binding assay serves multiple functions simultaneously: it identifies and quantifies various product-related variants, assesses their impact on binding affinity, and characterizes CQAs all in a single workflow. This multi-functional approach replaces multiple specialized assays.
2Productivity
If multiple product-related variants are assessed simultaneously, then productivity is improved, but device complexity increases
Solution Approach 1:
The patent uses the target molecule as an intermediary to indirectly assess multiple product-related variants. Instead of directly detecting each variant type, the method measures their competitive binding behavior to the target, simplifying the detection mechanism while enabling simultaneous assessment of multiple variants.
Solution Approach 2:
The patent replaces complex physical separation and detection systems with a biochemical competition assay. Instead of using multiple specialized instruments for separating and detecting different variant types, a single binding assay with mass spectrometry detection suffices to characterize all variants.
3Measurement precision
If laborious enrichment procedures are used for product-related impurities, then measurement precision is improved, but loss of time increases
Solution Approach 1:
The patent performs preliminary enrichment of product-related variants through the competitive binding process itself. By incubating the biologics with the target under conditions that allow variants to compete for binding, the method automatically concentrates variants with impaired binding in the unbound fraction, eliminating separate enrichment steps.
Solution Approach 2:
The patent extracts information about product-related variants indirectly by measuring their effect on target binding. Instead of extracting and analyzing each variant type separately, the method extracts binding affinity data from the competitive assay, from which variant characteristics are derived.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for the efficient and simultaneous assessment of multiple product-related variants, improving the characterization of CQAs and reducing the complexity of evaluating their impact on binding affinity and product stability.
Implementation Method 1
contacting said sample to a competitive binding condition including an insufficient target immobilized on beads
Implementation Method 2
subjecting said flow-through to liquid chromatography-mass spectrometry analysis to separate said protein of interest and said at least one product-related variant
Implementation Method 3
quantification, for example using UV detection and/or mass spectrometry
Data Source
AI summary
The present invention relates to the field of protein characterization, and in particular to methods for identifying critical quality attributes of therapeutic proteins by implementing a workflow including using a competitive binding assay with insufficient capture molecule followed by LC-MS.